SAB Biotherapeutics Approves Appointment of Andrew Moin to Board of Directors
SIOUX FALLS, S.D., Oct. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that the SAB Board of Directors has approved the appointment of Andrew Moin to the Company’s Board of Directors.
- SIOUX FALLS, S.D., Oct. 05, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS ), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that the SAB Board of Directors has approved the appointment of Andrew Moin to the Company’s Board of Directors.
- With Mr. Moin’s appointment, SAB Biotherapeutics’ Board is composed of nine directors, seven of whom are independent.
- “The entire team at SAB Biotherapeutics is most grateful Andrew has accepted a position on the Company’s Board of Directors,” said Samuel J. Reich, Executive Chairman of SAB.
- “With Andrew’s appointment, SAB is strengthening its commitment to fighting type 1 diabetes and advancing our lead therapeutic candidate, SAB-142.